Search

Your search keyword '"Kelly, Thu-Lan"' showing total 207 results
Start Over Author "Kelly, Thu-Lan"
207 results on '"Kelly, Thu-Lan"'

4. Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries

Author

Al-Dabbous, Tala, Alfoudri, Huda, Shamsah, Mohammed, Alfroukh, Khadeejeh, Bairmani, Zinah Aqeel Abdulzahra, Khalid, Khalid Jehad, Abukhalaf, Salsabeel M.A., Hadhoud, Mohammed Maher, Abdrabo, Mohamed Fouad, Fathi, Mohamed, Alhouri, Hasan, Shahla, Dr Hamza, Alhadad, Qamrah, Hanan, Matly, Elapavaluru, Subbarao, Berg, Ashley, Horn, Christina, Abdelhalim, Ahmed Reda Mohamed Elsayed, Amer, Amro Essam, Elnaggar, Cinderella Omar Rageh, Hassan, Ahmed Ayman, Abdelaziz, Ali, Abdelhalim, Mohamed, Orabi, Yehia Samir Shaaban Aly, Alaraji, Zinah A., Muhaisen, Mo'nes R., Almasri, Lana, Mustafa, Dana, Hamdan, Shaher, Al-Saba'a, Yousef, Dalloul, Zaina, Alkahlout, Mohammed, Jaber, Hamza, Aldabbourosama, Osama, Abdalhadi, Alaa Abdalfattah, Hussein, Aliae AR Mohamed, Emad, Zarief Kamel, Khaled, Sarah, Mohamed, Nouralsabah, Hassanin, Ebtisam, Hamdi, Abdelhafeez, Gamal, May, Emad, Ahmed, Ragab, Abdelrahman, Azizeldin, Mohammed G, Hamza, Almthani, Omer, Alsarrah Ali Mohammed, Fadl alla, Asgad Osman Abdalla, Abdallahrs, Asia Atif Abdelrahman, Eltayeb, Aml Ahmed, Alhasan, Maali khalid mohamed abdalla, Abdelgaum, Esraa Hassan, Ahmed, Aya Mustafa, Abdulbaqi, Lamees Adil, Mohammedelhassan, Omer Abdullah, Ahmed, Musaab Mohammed Mohammed, Ali, Maha TagElser Mohammed, Mayasi, Yunis, Schroll, Stephan, Meyer, Dan, Velazco, Jorge, Ploskanych, Ludmyla, Fikes, Wanda, Bagewadi, Rohini, Dao, Marvin, White, Haley, Laviena, Alondra Berrios, Ehlers, Ashley, Shalabi-McGuire, Maysoon, Witt, Trent, Grazioli, Lorenzo, Lorini, Luca, Grandin, E. Wilson, Nunez, Jose, Reyes, Tiago, O'Briain, Diarmuid, Hunter, Stephanie, Ramanan, Mahesh, Affleck, Julia, Veerendra, Hemanth Hurkadli, Rai, Sumeet, Russell-Brown, Josie, Nourse, Mary, Joseph, Mark, Mitchell, Brook, Tenzer, Martha, Abe, Ryuzo, Cho, Hwa Jin, Jeong, In Seok, Rahman, Nadeem, Kakar, Vivek, Tamimi, Ahmed, Zabalawi, Diala, Elhennawi, Mohamed, Ghisulal, Praveen, Malik, Sadaf, Brozzi, Nicolas, Mehkri, Omar, Krishnan, Sudhir, Duggal, Abhijit, Houltham, Stuart, Graf, Jerónimo, Diaz, Roderigo, Orrego, Roderigo, Delgado, Camila, González, Joyce, Sanchez, Maria Soledad, Piagnerelli, Michael, Sarrazin, Josefa Valenzuela, Zabert, Prof. Gustavo, Espinosa, Lucio, Delgado, Paulo, Delgado, Victoria, Rincón, Diego Fernando Bautista, Yanten, Angela Maria Marulanda, Duque, Melissa Bustamante, Brodie, Daniel, Abouelmagd, Khaled, Elhazmi, Alyaa, Al-Hudaib, Abdullah, Javidfar, Jeff, Callahan, Maria, Dong, Andy, D'Orleans, Charles Crepy, Taufik, M. Azhari, Wardoyo, Elizabeth Yasmin, Gunawan, Margaretha, Trisnaningrum, Nurindah S, Irawany, Vera, Rayhan, Muhammad, Panigada, Mauro, Pesenti, Antonio, Zanella, Alberto, Grasselli, Giacomo, Colombo, Sebastiano, Martinet, Chiara, Florio, Gaetano, Antonelli, Massimo, Carelli, Simone, Grieco, Domenico L., Asaki, Motohiro, Hoshino, Kota, Salazar, Leonardo, Monsalve, Mary Alejandra Mendoza, Laffey, John, McNicholas, Bairbre, Cosgrave, David, Atif, Minha, Qutishat, Fadi, Laffey, Caoimhe, Van Der Walt, Michaeal, McCaffrey, Joseph, Bone, Allison, Trickey, Jemma, Horton, Michelle, Pearce, Stephanie, Salerno, Tania, Mohamed, Akram, Alhaddad, Salem, Bakeer, Baliad, Haitam, Shames, Shalabi, Laila, Ahmed, Mohammed Abodina, Hakeem, Yusuff, Winearls, James, Tallott, Mandy, Thomson, David, Joubert, Ivan, Arnold-Day, Christel, Piercy, Jenna, Smit, Richard van Zyl, Miller, Malcom, Seymour, Lisa, van Heyningen, Francois, Teyangesikayi, Gilbert, Fredericks, David, Hssain, Ali Ait, Aliudin, Jeffrey, Alqahtani, Al-Reem, Mohamed, Khoulod, Mohamed, Ahmed, Tan, Darwin, Villanueva, Joy, Zaqout, Ahmed, Labib, Ahmed, Kurtzman, Ethan, Ademi, Arben, Dobrita, Ana, Aoudi, Khadija El, Segura, Juliet, Giwangkancana, Gezy, Ohshimo, Shinichiro, Osatnik, Javier, Joosten, Anne, Torres, Antoni, Yang, Minlan, Motos, Ana, Luna, Carlos, Arancibia, Francisco, Williams, Virginie, Noel, Alexandre, Luque, Nestor, Fantini, Marina, García, Ruth Noemi Jorge, Alvarez, Enrique Chicote, Greti, Anna, Ceccato, Adrian, Sanchez, Angel, Vazquez, Ana Loza, Roche-Campo, Ferran, Franch-Llasat, Diego, Tuazon, Divina, Amato, Marcelo, Cassimiro, Luciana, Pola, Flavio, Ribeiro, Francis, Fonseca, Guilherme, Dalton, Heidi, Desai, Mehul, Osborn, Erik, Deeb, Hala, Arcadipane, Antonio, Martucci, Gennaro, Panarello, Giovanna, Vitiello, Stefano, Bianco, Claudia, Occhipinti, Giovanna, Rossetti, Matteo, Cuffaro, Raffaele, Siddig, Nidhal, Cho, Sung-Min, Whitman, Glenn, Sayed, Marwan El, Mokhtar, Walaa, El-Shenawy, Eslam, Shimizu, Hiroaki, Moriyama, Naoki, Kim, Jae-Burm, Kitamura, Nobuya, Gebauer, Johannes, Yokoyama, Toshiki, Al-Fares, Abdulrahman, Buabbas, Sarah, Alamad, Esam, Alawadhi, Fatma, Alawadi, Kalthoum, Khalefa, Mohamed Ahmed, Ajeel, Nourah Ahmad Abdulaziz Al, Aly, Mohammad Fathy, Al-Saleh, Abdullah, Naanouh, Abdullah, Elshourbgy, Alaa Mohammed, Gad, Mohamed Yousef, ElRazaz, Rania Mohamed, Khadadah, Ibrahim, Almumin, Ahmed Mohammed, Altarakma, Hala, Albannay, Hasan, Alsaleh, Mohammed Kh, Radwan, Mahmoud Saad Abdallah, Saadallah, Islam Ahmed, Tanaka, Hiro, Hashimoto, Satoru, Yamazaki, Masaki, Oh, Tak-Hyuck, Epler, Mark, Forney, Cathleen, Kruse, Louise, Feister, Jared, Williamson, Joelle, Grobengieser, Katherine, Gnall, Eric, Golden, Sasha, Caroline, Mara, Shapiro, Timothy, Karaj, Colleen, Thome, Lisa, Sher, Lynn, Vanderland, Mark, Welch, Mary, McDermott, Sherry, Brain, Matthew, Mineall, Sarah, Unwin, Maria, Chen, Lixian, Trezise, Tarnya, McKeon, Laurie, Kimura, Dai, Brazzi, Luca, Sales, Gabriele, Montrucchio, Giorgia, Ogston, Tawnya, Nagpal, Dave, Fischer, Karlee, Lorusso, Roberto, van Bussell, Bas, De Piero, Maria Elena, Mariani, Silvia, Rangappa, Dr Rajavardhan, Shetty, Dr Rajesh Mohan, P, Sujin Rai, Ganesan, Argin, Tharwat, Samar, Esperatti, Mariano, Fuentes, Nora Angélica, Gonzalez, Maria Eugenia, Carton, Edmund G., Sen, Ayan, Palacios, Amanda, Rainey, Deborah, Samoukoviv, Gordan, Campisi, Josie, Durham, Lucia, Neumann, Emily, Seefeldt, Cassandra, Falcucci, Octavio, Emmrich, Amanda, Guy, Jennifer, Johns, Carling, Potzner, Kelly, Zimmermann, Catherine, Espinal, Angelia, Buchtele, Nina, Schwameis, Michael, Korhnfehl, Andrea, Brock, Roman, Staudinger, Thomas, Stecher, Stephanie-Susanne, Barnikel, Michaela, Antón, Sófia, Pawlikowski, Alexandra, Zaaqoq, Akram, Galloway, Lan Anh, Merley, Caitlin, Muftah, Mohamed, Nichol, Alistair, Csete, Marc, Quesada, Luisa, Saba, Isabela, Kasugai, Daisuke, Hiraiwa, Hiroaki, Tanaka, Taku, Marwali, Eva, Purnama, Yoel, Dewayanti, Santi Rahayu, Ardiyan, Juzar, Dafsah Arifa, Siagian, Debby, Chen, Yih-Sharng, Aldhalia, Amer, Ogino, Mark, Nasa, Prashant, Matthew, Christina, Majeed, Nimisha Abdul, Hafez, Wael, Ratsep, Indrek, Post, Andra-Maris, Sillaots, Piret, Krund, Anneli, Lehiste, Merili-Helen, Lepik, Tanel, Manetta, Frank, Mihelis, Effe, Sarmiento, Iam Claire, Narasimhan, Mangala, Varrone, Michael, Komats, Mamoru, Garcia-Diaz, Julia, Harmon, Catherine, Satyapriya, S. Veena, Bhatt, Amar, Mokadam, Nahush A., Uribe, Alberto, Gonzalez, Alicia, Shi, Haixia, McKeown, Johnny, Pasek, Joshua, Fiorda, Juan, Echeverria, Marco, Moreno, Rita, Zakhary, Bishoy, Cavana, Marco, Cucino, Alberto, Foti, Giuseppe, Giani, Marco, Fumagalli, Benedetta, Chiumello, Davide, Castagna, Valentina, Dell'Amore, Andrea, Navalesi, Paolo, Shum, Hoi-Ping, Vuysteke, Alain, Usman, Asad, Acker, Andrew, Smood, Benjamin, Mergler, Blake, Sertic, Federico, Subramanian, Madhu, Sperry, Alexandra, Rizer, Nicolas, Burhan, Erlina, Rasmin, Menaldi, Akmal, Ernita, Sitompul, Faya, Lolong, Navy, Naivedh, Bhat, Erickson, Simon, Barrett, Peter, Dean, David, Daugherty, Julia, Loforte, Antonio, Khan, Irfan, Quraishi, Mohammed Abraar, DeSantis, Olivia, Nasrallah, Ahmad, So, Dominic, Kandamby, Darshana, Mandei, Jose M., Natanael, Hans, YudhaLantang, Eka, Lantang, Anastasia, Wijaya, Surya Oto, Jung, Anna, Ng, George, Ng, Wing Yiu, Ng, Pauline Yeung, Fang, Shu, Tabah, Alexis, Ratcliffe, Megan, Duroux, Maree, Alajeeli, Ahmed, Tarhabat, Ali, Adachi, Shingo, Nakao, Shota, Blanco, Pablo, Prieto, Ana, Sánchez, Jesús, Nicholson, Meghan, Butt, Warwick, Serratore, Alyssa, Delzoppo, Carmel, Janin, Pierre, Yarad, Elizabeth, Totaro, Richard, Coles, Jennifer, Pujo, Bambang, Balk, Robert, Vissing, Andy, Kapania, Esha, Hays, James, Fox, Samuel, Yantosh, Garrett, Mishin, Pavel, Adem, Safia, Yuliarto, Saptadi, Santoso, Kohar Hari, Djajalaksana, Susanthy, Fatoni, Arie Zainul, Fukuda, Masahiro, Liu, Keibun, Pelosi, Paolo, Battaglini, Denise, Robba, Chiara, Jiménez, Juan Fernando Masa, Bastos, Diego, Gaião, Sérgio, Rusmawatiningtyas, Desy, Cho, Young-Jae, Lee, Su Hwan, Kawasaki, Tatsuya, Munshi, Laveena, Sakiyalak, Pranya, Nitayavardhana, Prompak, Elagili, Mohamed Bashir, Salem, Talat Ahmed Abu, Seitz, Tamara, Arora, Rakesh, Kent, David, Marino, Daniel, Parwar, Swapnil, Cheng, Andrew, Miller, Jennene, Fujitani, Shigeki, Shimizu, Naoki, Madhok, Jai, Owyang, Clark, Buscher, Hergen, Reynolds, Claire, Abdurraouf, Abusalama, Kredan, Ali Abdulnasir, Haddud, Abdurrahman, Moharam, Saad, Maasikas, Olavi, Beljantsev, Aleksan, Mihnovits, Vladislav, Akimoto, Takako, Aizawa, Mariko, Horibe, Kanako, Onodera, Ryota, Hodgson, Carol, Burrell, Aidan, Young, Meredith, George, Timothy, Shekar, Kiran, McGuinness, Niki, Irvine, Lacey, Flynn, Brigid, Almjersah, Abdulrahman, Bakri, Ashraf, Endo, Tomoyuki, Sugiyama, Kazuhiro, Shimizu, Keiki, Fan, Eddy, Exconde, Kathleen, Ichiba, Shingo, Binnawara, Muhannud, Embarek, Hussein, Lussier, Leslie, Lotz, Gösta, Malfertheiner, Maximilian, Maier, Lars, Dreier, Esther, Kusumastuti, Neurinda Permata, McCloskey, Colin, Dabaliz, Al-Awwab, Elshazly, Tarek B, Smith, Josiah, Szuldrzynski, Konstanty S., Bielański, Piotr, Wille, Keith, Murthy, Srinivas, Parhar, Ken Kuljit S., Fiest, Kirsten M., Codan, Cassidy, Shahid, Anmol, Fayed, Mohamed, Evans, Timothy, Garcia, Rebekah, Gutierrez, Ashley, Song, Tae, Rose, Rebecca, Bennett, Suzanne, Richardson, Denise, Peek, Giles, Arora, Lovkesh, Rappapport, Kristina, Rudolph, Kristina, Sibenaller, Zita, Stout, Lori, Walter, Alicia, Herr, Daniel, Vedadi, Nazli, Bartlett, Robert, Thompson, Shaun, Hoffman, Julie, Ying, Xiaonan, Williams, Bailey, Sanchez, Emely, Akwani, Chika, Kennedy, Ryan, Elhadi, Muhammed, Griffee, Matthew, Mone, Mary, Ciullo, Anna, Kida, Yuri, Roca, Ricard Ferrer, Riera, JordI, Contreras, Sofia, Alegre, Cynthia, Kay, Christy, Fischer, Irene, Renner, Elizabeth, Taniguci, Hayato, Lee, James, Plotkin, Daniel, Citarella, Barbara Wanjiru, Merson, Laura, Hartley, Emma, Lubis, Bastian, Ikeyama, Takanari, Mortada, Alshaymaa, Alhamad, Ameen, Mechi, Ahmed, Nadar, Islam Mohsen Ali Mohamed Hassan, Alyasiri, Mohammed Saleh, Elsaid, Muhammed Zainab Alghali, Bhaskar, Balu, Jung, Jae-Seung, McGuinness, Shay, Eastwood, Glenn, Marta, Sandra Rossi, Guarracino, Fabio, Gerle, Stacy, Coxon, Emily, Claro, Bruno, Aldressi, Wafa, Eleisawy, Mahmoud, Osama, Hasnaa, Loverde, Daniel, Patil, Namrata, Parrini, Vieri, McBride, Angela, Negaard, Kathryn, Ratsch, Angela, Abdelaziz, Ahmad, Uribe, Juan David, Peris, Adriano, Sanders, Mark, Emerson, Dominic, Kamal, Muhammad, Faida, Hamza, Povoa, Pedro, Francis, Roland, Cherif, Ali, Joseph, Sunimol, Nardo, Matteo Di, Heard, Micheal, Kyle, Kimberly, Blackwell, Ray A, OUYAHIA, Amel, Biston, Patrick, Jeong, Hye Won, Smith, Reanna, Prawira, Yogi, Garcia, Arturo Huerta, Salterain, Nahikari, Meyns, Bart, Elnasser, Muhammed, Moreno, Marsha, Walia, Rajat, Mehta, Amit, Schweda, Annette, Williams, Melissa, Amkhatirah, Emad, Kim, Kyung Hoon, Assad, Alexandra, Giraldo, Estefania, Karolak, Wojtek, Balik, Martin, Pocock, Elizabeth, Gajkowski, Evan, Bedair, Mohamed, Masafumi, Kanamoto, Barrett, Nicholas, Takeyama, Yoshihiro, Park, Sunghoon, Amin, Faizan, Andriyani, Fina Meilyana, Sudakevych, Serhii, Schnur, Janos, Vera, Magdalena, Cornejo, Rodrigo, Schwarz, Patrícia, Mardini, Ana Carolina, de Paula, Thais, Neto, Ary Serpa, Villoldo, Andrea, Colafranceschi, Alexandre Siciliano, Iglesias, Alejandro Ubeda, Granjean, Juan, Melro, Lívia Maria Garcia, Romualdo, Giovana Fioravante, Gaia, Diego, Souza, Helmgton, Galas, Filomena, Mendiluce, Rafael Máñez, Sosa, Alejandra, Martinez, Ignacio, Kurosawa, Hiroshi, Almoshantaf, Mohammad Badr, Salgado, Juan, Hugi-Mayr, Beate, Charbonneau, Eric, Barzilai, Vitor Salvatore, Monteiro, Veronica, de Souza, Rodrigo Ribeiro, Harper, Michael, Suzuki, Hiroyuki, Adams, Celina, Brieva, Jorge, Khamees, Almu'atasim, Graige, Fadi, Supriatna, Moh, Nyale, George, Eltatar, Faisal Saleem, Fatani, Jihan, Baeissa, Husam, Masri, Ayman AL, Rabie, Ahmed, Hui, Mok Yee, Yamane, Masahiro, Jung, Hanna, Margaret, Ayorinde Mojisola, Nacpil, Newell, Ruck, Katja, Bakken, Rhonda, Jara, Claire, Felton, Tim, Berra, Lorenzo, Shah, Bobby, Chakraborty, Arpan, Cardona, Monika, Capatos, Gerry, Akkanti, Bindu, Orija, Abiodun, Jain, Harsh, Ito, Asami, Housni, Brahim, Low, Sennen, Iihara, Koji, Chavez, Joselito, Ramanathan, Kollengode, Zabert, Gustavo, Naidoo, Krubin, Seppelt, Ian, VanDyk, Marlice, MacDonald, Sarah, McGregor, Randy, Siebenaler, Teka, Flynn, Hannah, Lofton, Kristi, Aokage, Toshiyuki, Kvirkvelia, Bakar, Shigemitsu, Kazuaki, Moscatelli, Andrea, Fiorentino, Giuseppe, Baumgaertel, Matthias, Mba, Serge Eddy, Assy, Jana, Hutahaean, Amelya, Roush, Holly, Sichting, Kay A, Alessandri, Francesco, Burns, Debra, Alkhubouli, Taha Husayn, Salt, Gavin, Garabedian, Carl P., Millar, Jonathan, Sim, Malcolm, Mattke, Adrian, McAuley, Danny, Tadili, Jawad, Frenzel, Tim, Abuleil, Amro, Bar-Lavie, Yaron, Ortiz, Aaron Blandino, Stone, Jackie, Attokaran, Antony, Farquharson, Michael, Patel, Brij, Gunning, Derek, Baillie, Kenneth, Watson, Pia, Tamai, Kenji, Saaid, Ayoub, Anania, Pasquale, Sajinadiyasa, Gede Ketut, Kanyawati, Dyah, Salgado, Marcello, Sassine, Assad, Yudo, Bhirowo, McCaul, Scott, Lee, Bongjin, Lee, Sang Min, Afek, Arnon, Fattouh, Shimaa E, Iwashita, Yoshiaki, Fadlalmola, Hammad, Semedi, Bambang Pujo, Mansour, Noureldin Mohamed, Metiva, Jack, Van Belle, Nicole, Martin-Loeches, Ignacio, Al-Sadawi, Dr Mohammed, Kirakli, Cenk, Shimaa, Al-Touny, Ivatt, Lenny, Woon, Chia Yew, Kang, Hyun Mi, Smith, Timothy, James, Erskine, Al-Rawas, Nawar, Iwasaki, Yudai, Ashour, Hamza, King-Chung, Kenny Chan, Gudzenko, Vadim, Taccone, Fabio, Perdhana, Fajar, Lamarche, Yoan, Ribeiro, Joao Miguel, Bradic, Nikola, Van den Bossche, Klaartje, Lansink, Oude, Singh, Gurmeet, Debeuckelaere, Gerdy, Stelfox, Henry T., Yi, Cassia, Elia, Jennifer, Tribble, Thomas, Shankar, Shyam, Padmanabhan, Raj, Hallinan, Bill, Paoletti, Luca, Leyva, Yolanda, Fykuda, Tatuma, Badulak, Jenelle, Koch, Jillian, Janowaik, Lisa, Hackman, Amy, Hernandez, Deb, Osofsky, Jennifer, Donadello, Katia, Lawang, Aizah, Fine, Josh, Davidson, Benjamin, Vazquez, Andres Oswaldo Razo, Abdehaleem, Ibrahim, Kelly, Thu-Lan, Fanning, Jonathon, Premraj, Lavienraj, Porto, Diego Bastos, White, Nicole M., Bassi, Gianluigi Li, Suen, Jacky, and Fraser, John F.

Published
2024
Full Text
View/download PDF

8. Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries.

Author

Battaglini, Denise, Kelly, Thu-Lan, Griffee, Matthew, Fanning, Jonathon, Premraj, Lavienraj, Whitman, Glenn, Porto, Diego Bastos, Arora, Rakesh, Thomson, David, Pelosi, Paolo, White, Nicole M., Bassi, Gianluigi Li, Suen, Jacky, Fraser, John F., Robba, Chiara, and Cho, Sung-Min

Abstract

• Global income inequality and disparities of healthcare resources have been exacerbated by the pandemic. • Coronavirus disease-2019 (COVID-19) causes severe respiratory distress as well as a slew of additional systemic consequences that affect several organ systems, including neurological complications. Ischemic stroke represents the most common neurological complication of respiratory failure due to COVID-19. • Stroke incidence per admitted days in patients with respiratory failure due to COVID-19 was low in high income countries (HICs) and low-middle income countries (LMICs) although the stroke risk was higher in LMICs. • Both LMIC status and stroke increased the risk of death in patients with respiratory failure due to COVID-19. We aimed to compare the incidence of stroke in low-and middle-income countries (LMICs) versus high-income countries (HICs) in critically ill patients with COVID-19 and its impact on in-hospital mortality. International observational study conducted in 43 countries. Stroke and mortality incidence rates and rate ratios (IRR) were calculated per admitted days using Poisson regression. Inverse probability weighting (IPW) was used to address the HICs vs. LMICs imbalance for confounders. 23,738 patients [20,511(86.4 %) HICs vs. 3,227(13.6 %) LMICs] were included. The incidence stroke/1000 admitted-days was 35.7 (95 %CI = 28.4–44.9) LMICs and 17.6 (95 %CI = 15.8–19.7) HICs; ischemic 9.47 (95 %CI = 6.57–13.7) LMICs, 1.97 (95 %CI = 1.53, 2.55) HICs; hemorrhagic, 7.18 (95 %CI = 4.73–10.9) LMICs, and 2.52 (95 %CI = 2.00–3.16) HICs; unspecified stroke type 11.6 (95 %CI = 7.75–17.3) LMICs, 8.99 (95 %CI = 7.70–10.5) HICs. In regression with IPW, LMICs vs. HICs had IRR = 1.78 (95 %CI = 1.31–2.42, p < 0.001). Patients from LMICs were more likely to die than those from HICs [43.6% vs 29.2 %; Relative Risk (RR) = 2.59 (95 %CI = 2.29–2.93), p < 0.001)]. Patients with stroke were more likely to die than those without stroke [RR = 1.43 (95 %CI = 1.19–1.72), p < 0.001)]. Stroke incidence was low in HICs and LMICs although the stroke risk was higher in LMICs. Both LMIC status and stroke increased the risk of death. Improving early diagnosis of stroke and redistribution of healthcare resources should be a priority. ACTRN12620000421932 registered on 30/03/2020. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Temporal trends in medical device implant procedures in Australia 2008–22: evidence from the Australian Institute of Health and Welfare National Hospital Morbidity database.

Author

Ali, Mohammad Afshar, Kelly, Thu-Lan, and Gillam, Marianne

Subjects
*PROSTHETICS, *DATABASES, *RESEARCH funding, *PATIENT safety, *SEX distribution, *HEALTH, *ARTIFICIAL implants, *AGE distribution, *TREND analysis, *HOSPITALS, *PROSTHETIC heart valves, *SURGICAL stents, *DESCRIPTIVE statistics, *OPERATIVE surgery, *DISEASES, *TOTAL knee replacement, *IMPLANTABLE cardioverter-defibrillators, *CARDIAC pacemakers, *BREAST implants, *CONFIDENCE intervals, *DATA analysis software, *EQUIPMENT & supplies, *SURGICAL meshes, *REGRESSION analysis
Abstract

Objective: Examine the temporal trends in medical device implant procedures in the Australian population. Methods: We used data from the Australian Institute of Health and Welfare from the financial years 2007–08 to 2021–22 and chose the most frequently performed medical device implant procedures. We estimated the annual change in volume of procedures and age-standardised rates by calculating the compound annual growth rate (CAGR), and used regression with the Newey–West robust variance estimator to examine whether there was a linear trend in the age-standardised rates for each procedure. Results: For procedures including cardiac pacemakers, heart valves, hip and knee arthroplasties, and intraocular lenses, the crude CAGR was over 3%. For the age-standardised rates, the CAGR was largest for cardiac pacemaker, followed by heart valve replacement and hip arthroplasty procedures. For some procedures, the growth was more than in the Australian population, including cardiac pacemakers (β = 1.00; 95% CI: 0.14–1.86), heart valve replacements (β = 0.41; 95% CI: 0.28–0.54), hip arthroplasty (β = 3.50; 95% CI: 1.61–5.38), and knee arthroplasty (β = 4.31; 95% CI: 0.54–8.09) procedures. The trend of standardised rates of procedures, including incisional hernia with mesh, breast implants, coronary stents, and cardiac defibrillators, grew at the same rate as the population, whereas the rate for gastric banding procedures decreased (β = −3.14; 95% CI: −4.92 to −1.34). Conclusion: The findings from the current study, showing a large increase in medical device implant procedures, will assist in future healthcare planning and efforts in post-market surveillance of safety of medical devices. What is known on this topic? Previous studies investigated trends in medical device implants on either a particular medical procedure or total procedures conducted on particular anatomical sites. What this study adds? Unlike previous studies, this study investigates a general population-level trend analysis of all major device implants using the most recent national-level database, covering all hospitals in Australia. What are the implications for practitioners? Findings from this study are useful for future healthcare planning and allocation of resources for the healthcare delivery of necessary healthcare to patients in Australia. In addition, the results can be used to inform efforts to improve post-marked surveillance of medical devices by providing estimates of the volume and standardised rates of procedures for type of devices. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Medicine utilization studies in Australian individual‐level dispensing data: A blinded, multi‐center replicated analysis

Author

Gillies, Malcolm B., primary, Bharat, Chrianna, additional, Camacho, Ximena, additional, Daniels, Benjamin, additional, Hall, Kelly, additional, Kelly, Thu‐Lan, additional, Kelty, Erin, additional, Lin, Jialing, additional, Litchfield, Melisa, additional, Lopez, Derrick, additional, Noghrehchi, Firouzeh, additional, Raubenheimer, Jacques, additional, Varney, Bianca, additional, and Pratt, Nicole, additional

Published
2024
Full Text
View/download PDF

13. CRISTAL (a cluster-randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study): statistical analysis plan

Author

Sidhu, Verinder Singh, Kelly, Thu-Lan, Pratt, Nicole, Graves, Steven, Buchbinder, Rachelle, Naylor, Justine, de Steiger, Richard, Ackerman, Ilana, Adie, Sam, Lorimer, Michelle, Bastiras, Durga, Cashman, Kara, and Harris, Ian

Published
2021
Full Text
View/download PDF

17. The weighted cumulative exposure method and its application to pharmacoepidemiology: A narrative review.

Author

Kelly, Thu‐Lan, Salter, Amy, and Pratt, Nicole L.

Abstract

Purpose: The weighted cumulative exposure (WCE) method has been used in a number of fields including pharmacoepidemiology where it can account for intensity, duration and timing of exposures on the risk of an outcome. The method uses a data driven approach with flexible cubic B‐splines to assign weights to past doses and select an aetiologically appropriate time window. Predictions of risk are possible for common exposure patterns encountered in real‐world studies. The purpose of this study was to describe applications of the WCE method to pharmacoepidemiology and assess the strengths and limitations of the method. Method: A literature search was undertaken to find studies applying the WCE method to the study of medicines. Articles published in PubMed using the search term 'weighted cumulative exposure' and articles citing Sylvestre et al. (2009) in Google Scholar or Scopus up to March 2023 were subsequently reviewed. Articles were selected based on title and review of abstracts. Results: Seventeen clinical applications using the data‐driven WCE method with flexible cubic splines were identified in the review. These included 3 case–control studies and 14 cohort studies, of which 12 were analysed with Cox proportional hazards models and 2 with logistic regression. Thirteen studies used time windows of 1 year or longer. Of 11 studies which compared conventional models with the WCE method, 10 (91%) studies found a better fit with WCE models while one had an equivalent fit. The freely available 'WCE' software package has facilitated the applications of the WCE method with flexible cubic splines. Conclusions: The WCE method allows additional insights into the effect of cumulative exposure on outcomes, including the timing and intensity (dose) of the exposure on the risk. The flexibility of the method is particularly well suited to studies with long‐term exposures that vary over time or where the current risk of an event is affected by how far the exposure is in the past, which is difficult to model with conventional definitions of exposure. Interpretation of the results can be more complex than for conventional models and would be facilitated by a standardised reporting framework. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Revision joint replacement surgeries of the hip and knee across geographic region and socioeconomic status in the western region of Victoria: a cross-sectional multilevel analysis of registry data

Author

Brennan-Olsen, Sharon L., Vogrin, Sara, Graves, Stephen, Holloway-Kew, Kara L., Page, Richard S., Sajjad, M. Amber, Kotowicz, Mark A., Livingston, Patricia M., Khasraw, Mustafa, Hakkennes, Sharon, Dunning, Trisha L., Brumby, Susan, Sutherland, Alasdair G., Talevski, Jason, Green, Darci, Kelly, Thu-Lan, Williams, Lana J., and Pasco, Julie A.

Published
2019
Full Text
View/download PDF

23. Evaluating whether KRAS/BRAF mutation status, anaemia and obstruction are associated with recurrence and mortality in non‐metastatic colorectal cancer.

Author

Juszczyk, Karolina, Afzal, Mohamed Zaafer, Ganguly, Timothy, Kelly, Thu‐Lan, Zeelie, Robyn, and Murphy, Elizabeth Mary Ann

Subjects
COLORECTAL cancer, BRAF genes, RAS oncogenes, CANCER relapse, PROPORTIONAL hazards models, ANEMIA, LARGE intestine
Abstract

Background: KRAS and BRAF testing is currently recommended in metastatic colorectal cancer. There is evidence that KRAS and BRAF mutation status may act as a prognostic biomarker in patients with non‐metastatic colorectal cancer. Data is limited on whether KRAS and BRAF mutation status impacts recurrence and mortality in patients with non‐metastatic colorectal cancer. Methods: A retrospective cohort study was conducted in a tertiary hospital examining outcomes in patients who had KRAS and BRAF testing for colorectal cancer in 2017. Primary outcomes were all‐cause mortality and recurrence. Multivariable analysis for both outcomes, used cause specific Cox proportional hazards models with KRAS/BRAF status as exposure. For time to recurrence, a sensitivity analysis was performed with a weighted Fine‐Grey model with death as a competing risk. Results: KRAS mutation status was not associated with all‐cause mortality (average Hazard Ratio (aHR) = 0.78, 95% CI 0.28–2.21) or recurrence (aHR = 0.96, 95% CI 0.32–2.86). BRAF mutation status was not associated with time to all‐cause mortality (aHR = 3.06, 95% CI 0.79–11.8) or recurrence (aHR = 0.94, 95% CI 0.13–6.57). Increased risk of recurrence was significantly associated with large bowel obstruction (aHR = 2.73, 95% CI 1.16–6.45) and anaemia (aHR = 3.39, 95% CI 1.06–10.8) at time of surgery. Conclusion: This study did not demonstrate an association between KRAS and BRAF mutations and all‐cause mortality or recurrence. A significantly increased risk of cancer recurrence was found in patients with large bowel obstruction and in patients with anaemia at time of surgery. Anaemia should be promptly investigated and corrected prior to colorectal cancer surgery. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Implementation of the South Australian Regional Telestroke service is associated with improved care quality and lower stroke mortality: A retrospective cohort study.

Author

Goh, Rudy, Hillier, Susan, Kelly, Thu‐Lan, Worley, Anthea, Dixon, Karen, Kurunawai, Craig, Tan, Aaron, Mahadevan, Joshua, Willcourt, Matthew, Jannes, Jim, and Kleinig, Timothy

Subjects
STROKE prevention, STROKE-related mortality, MEDICAL quality control, OCCUPATIONAL roles, KRUSKAL-Wallis Test, NEUROLOGY, CONFIDENCE intervals, MEDICAL triage, RURAL conditions, RESEARCH methodology, AMBULANCES, RETROSPECTIVE studies, RESEARCH funding, DESCRIPTIVE statistics, QUALITY assurance, PHYSICIANS, TELEMEDICINE, LONGITUDINAL method
Abstract

Introduction: Stroke in Regional Australia may have worse outcomes due to difficulties accessing optimal care. The South Australian Regional Telestroke service aimed to improve telestroke neurologist access, supported by improved ambulance triage. Objective: To assess stroke care quality and patient mortality pre‐ and postimplementation of a vascular neurologist‐led Telestroke service. Design: Historically controlled mixed methods cohort study comparing key quality indicators and patient mortality (6 months pre‐ vs. 18 months postimplementation date [4 June 2018]) at the three major South Australian regional stroke centres. The primary outcome was 13 care quality indicators as a combined composite risk‐adjusted score, and the secondary outcome was risk‐adjusted mortality at 12‐month postadmission. Findings: On an annualised basis, of 189 patients with stroke, more were admitted postintervention to the regional stroke centres than in the control period (158 [annualised rate 105.3, 95% CI 86.2–127.4] vs. 31 [annualised rate 62.0, 95% CI 47.5–79.5]) Baseline patient characteristics were similar in both periods. Post‐implementation, median last‐known‐well time to presentation (3.5 h [IQR 1.6–17] vs. 2.0 [IQR 1–14]; p = 0.46) and door to needle times (121 min [IQR 97–144] vs. 90 [IQR 75–138]; p = 0.65) were not significantly lower but an improvement in the combined composite quality score was observed (0.069 [95% CI 0.004–0.134; p = 0.04]), reflecting individual improvements in some quality indicators. Mortality at 12‐month postimplementation was substantially lower postimplementation (prechange 23% vs. postchange 13% [hazard ratio 0.58 (95% CI 0.44–0.76; p < 0.001)]). Conclusion: Implementation of a South Australian Regional Telestroke service was associated with improved care metrics and lower mortality. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. Correction to: Risk factors predictive of adverse drug events and drug-related falls in aged care residents: secondary analysis from the ReMInDAR trial

Author

Dorj, Gereltuya, primary, Nair, Nibu Parameswaran, additional, Bereznicki, Luke, additional, Kelly, Thu-Lan, additional, Pratt, Nicole, additional, Kalisch-Ellett, Lisa, additional, Andrade, Andre, additional, Rowett, Debra, additional, Whitehouse, Joseph, additional, Widagdo, Imaina, additional, Bilton, Rebecca L., additional, Lim, Renly, additional, and Roughead, Elizabeth, additional

Published
2022
Full Text
View/download PDF

29. Risk factors predictive of adverse drug events and drug-related falls in aged care residents: secondary analysis from the ReMInDAR trial

Author

Dorj, Gereltuya, primary, Nair, Nibu Parameswaran, additional, Bereznicki, Luke, additional, Kelly, Thu-Lan, additional, Pratt, Nicole, additional, Kalisch-Ellett, Lisa, additional, Andrade, Andre, additional, Rowett, Debra, additional, Whitehouse, Joseph, additional, Widagdo, Imaina, additional, Bilton, Rebecca L., additional, Lim, Renly, additional, and Roughead, Elizabeth, additional

Published
2022
Full Text
View/download PDF

32. Dual mobility versus conventional total hip arthroplasty in femoral neck fractures (DISTINCT): protocol for a registry-nested, open-label, cluster-randomised crossover trial

Author

Farey, John E, primary, Hooper, Tamara, additional, Alland, Tania, additional, Naylor, Justine M, additional, Kelly, Thu-Lan, additional, Lorimer, Michelle, additional, Lewin, Adriane M, additional, Rogers, Margaret, additional, Law, Chi Kin, additional, Close, Jacqueline, additional, Graves, Steven E, additional, de Steiger, Richard S, additional, Lewis, Peter L, additional, Adie, Sam, additional, and Harris, Ian A, additional

Published
2022
Full Text
View/download PDF

35. Wrist accelerometer temporal analysis as a prognostic tool for aged care residents: A sub‐study of the ReMInDAR trial.

Author

Andrade, Andre Q., Lim, Renly, Kelly, Thu‐Lan, Parfitt, Gaynor, Pratt, Nicole, and Roughead, Elizabeth E.

Subjects
COGNITION disorders, CONFIDENCE intervals, ACCELEROMETERS, ACTIGRAPHY, RISK assessment, HOSPITAL care, DESCRIPTIVE statistics, RESEARCH funding, DEATH, ODDS ratio, LOGISTIC regression analysis, ELDER care, SECONDARY analysis
Abstract

Background: Objective measures for screening, prioritizing, and planning care for frail individuals are essential for appropriate aged care provision. This study evaluates metrics derived from actigraphy measures (captured by wrist accelerometer) as a digital biomarker to identify frail individuals at risk of adverse outcomes, including death, hospitalization, and cognitive decline. Methods: This was a secondary study using data from a randomized controlled trial assessing the effectiveness of an ongoing pharmacist service in residential aged care facilities. Three metrics are studied and compared: the Frailty Index, the daily time spent in light time activity, and the temporal correlation of the actigraphy signal, measured by detrended fluctuation analysis. The association between actigraphy‐derived metrics at baseline and adverse events within 12 months (death, cognitive decline, and hospitalizations) was assessed using logistic regression. Results: Actigraphy records were available for 213 participants living in aged‐care, median age of 85 years. Individuals with higher temporal correlation (activity is less random) were at lower risk of death (Standardized OR: 0.49; 95% CI 0.34, 0.7, p < 0.001) and hospitalization (Standardized OR: 0.57; 95% CI 0.42, 0.77, p < 0.001) in 12 months, but there was no difference in cognitive decline (Standardized OR: 1; 95% CI 0.74, 1.35, p = 0.98). The predictive model that included temporal correlation had an area under the curve of 0.70 (CI 0.60–0.80) for death and 0.64 (CI 0.54–0.72) for hospitalization. Conclusion: Temporal correlation of the actigraphy signal from aged care residents was strongly associated with death and hospitalization, but not cognitive decline. Digital biomarkers may have a place as an objective, accurate, and low‐cost patient metric to support risk stratification and clinical planning. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

36. Effect of an ongoing pharmacist service to reduce medicine-induced deterioration and adverse reactions in aged-care facilities (nursing homes): a multicentre, randomised controlled trial (the ReMInDAR trial)

Author

Roughead, Elizabeth E, primary, Pratt, Nicole L, additional, Parfitt, Gaynor, additional, Rowett, Debra, additional, Kalisch-Ellett, Lisa M, additional, Bereznicki, Luke, additional, Merlin, Tracy, additional, Corlis, Megan, additional, Kang, Ai Choo, additional, Whitehouse, Joseph, additional, Bilton, Rebecca, additional, Schubert, Camille, additional, Torode, Stacey, additional, Kelly, Thu-Lan, additional, Andrade, Andre Q, additional, Post, Dannielle, additional, Dorj, Gereltuya, additional, Cousins, Justin, additional, Williams, Mackenzie, additional, and Lim, Renly, additional

Published
2022
Full Text
View/download PDF

38. Testing equivalence of two doses of intravenous iron to treat iron deficiency in pregnancy: A randomised controlled trial.

Author

Froessler, Bernd, Schubert, Klaus Oliver, Palm, Peter, Church, Richard, Aboustate, Natalie, Kelly, Thu‐Lan, Dekker, Gus A., and Hodyl, Nicolette A.

Subjects
IRON, IRON deficiency, RANDOMIZED controlled trials, IRON in the body, PREGNANCY
Abstract

Objective: To test the equivalence of two doses of intravenous iron (ferric carboxymaltose) in pregnancy. Design: Parallel, two‐arm equivalence randomised controlled trial with an equivalence margin of 5%. Setting: Single centre in Australia. Population 278 pregnant women with iron deficiency. Methods: Participants received either 500 mg (n = 152) or 1000 mg (n = 126) of intravenous ferric carboxymaltose in the second or third trimester. Main outcome measures: The proportion of participants requiring additional intravenous iron (500 mg) to achieve and maintain ferritin >30 microg/L (diagnostic threshold for iron deficiency) at 4 weeks post‐infusion, and at 6 weeks, and 3‐, 6‐ and 12‐months postpartum. Secondary endpoints included repeat infusion rate, iron status, birth and safety outcomes. Results: The two doses were not equivalent within a 5% margin at any time point. At 4 weeks post infusion, 26/73 (36%) participants required a repeat infusion in the 500‐mg group compared with 5/67 (8%) in the 1000‐mg group: difference in proportions, 0.283 (95% confidence interval [CI] 0.177–0.389). Overall, participants in the 500‐mg arm received twice the repeat infusion rate (0.81 [SD = 0.824] versus 0.40 [SD = 0.69], rate ratio 2.05, 95% CI 1.45–2.91). Conclusions: Administration of 1000 mg ferric carboxymaltose in pregnancy maintains iron stores and reduces the need for repeat infusions. A 500‐ mg dose requires ongoing monitoring to ensure adequate iron stores are reached and sustained. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial.

Author

Sidhu, Verinder S., Kelly, Thu-Lan, Pratt, Nicole, Graves, Stephen E., Buchbinder, Rachelle, Adie, Sam, Cashman, Kara, Ackerman, Ilana, Bastiras, Durga, Brighton, Roger, Burns, Alexander W. R., Chong, Beng Hock, Clavisi, Ornella, Cripps, Maggie, Dekkers, Mark, de Steiger, Richard, Dixon, Michael, Ellis, Andrew, Griffith, Elizabeth C., and Hale, David

Subjects
*ENOXAPARIN, *RESEARCH, *VEINS, *TOTAL hip replacement, *TOTAL knee replacement, *PULMONARY embolism, *RESEARCH methodology, *ANTICOAGULANTS, *EVALUATION research, *COMPARATIVE studies, *RANDOMIZED controlled trials, *LOW-molecular-weight heparin, *THROMBOEMBOLISM, *ASPIRIN, *OSTEOARTHRITIS, *CHEMOPREVENTION, PREVENTION of surgical complications, THROMBOEMBOLISM prevention
Abstract

Importance: There remains a lack of randomized trials investigating aspirin monotherapy for symptomatic venous thromboembolism (VTE) prophylaxis following total hip arthroplasty (THA) or total knee arthroplasty (TKA).Objective: To determine whether aspirin was noninferior to enoxaparin in preventing symptomatic VTE after THA or TKA.Design, Setting, and Participants: Cluster-randomized, crossover, registry-nested trial across 31 hospitals in Australia. Clusters were hospitals performing greater than 250 THA or TKA procedures annually. Patients (aged ≥18 years) undergoing hip or knee arthroplasty procedures were enrolled at each hospital. Patients receiving preoperative anticoagulation or who had a medical contraindication to either study drug were excluded. A total of 9711 eligible patients were enrolled (5675 in the aspirin group and 4036 in the enoxaparin group) between April 20, 2019, and December 18, 2020. Final follow-up occurred on August 14, 2021.Interventions: Hospitals were randomized to administer aspirin (100 mg/d) or enoxaparin (40 mg/d) for 35 days after THA and for 14 days after TKA. Crossover occurred after the patient enrollment target had been met for the first group. All 31 hospitals were initially randomized and 16 crossed over prior to trial cessation.Main Outcomes and Measures: The primary outcome was symptomatic VTE within 90 days, including pulmonary embolism and deep venous thrombosis (DVT) (above or below the knee). The noninferiority margin was 1%. Six secondary outcomes are reported, including death and major bleeding within 90 days. Analyses were performed by randomization group.Results: Enrollment was stopped after an interim analysis determined the stopping rule was met, with 9711 patients (median age, 68 years; 56.8% female) of the prespecified 15 562 enrolled (62%). Of these, 9203 (95%) completed the trial. Within 90 days of surgery, symptomatic VTE occurred in 256 patients, including pulmonary embolism (79 cases), above-knee DVT (18 cases), and below-knee DVT (174 cases). The symptomatic VTE rate in the aspirin group was 3.45% and in the enoxaparin group was 1.82% (estimated difference, 1.97%; 95% CI, 0.54%-3.41%). This failed to meet the criterion for noninferiority for aspirin and was significantly superior for enoxaparin (P = .007). Of 6 secondary outcomes, none were significantly better in the enoxaparin group compared with the aspirin group.Conclusions and Relevance: Among patients undergoing hip or knee arthroplasty for osteoarthritis, aspirin compared with enoxaparin resulted in a significantly higher rate of symptomatic VTE within 90 days, defined as below- or above-knee DVT or pulmonary embolism. These findings may be informed by a cost-effectiveness analysis.Trial Registration: ANZCTR Identifier: ACTRN12618001879257. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. Accurate and precise optical testing with a differential Hartmann wavefront sensor

Author

Kelly, Thu-Lan, Veitch, Peter J., Brooks, Aidan F., and Munch, Jesper

Subjects
Optical detectors -- Usage, Astronomy, Physics
Abstract

A novel differential Hartmann sensor is described. It can be used to determine the characteristics of an optic accurately, precisely, and simply without detailed knowledge of the wavefront used to illuminate the optical system or of the geometry of the measurement system. We demonstrate the application of this sensor to both zonal and modal optical testing of lenses. We also describe a dual-camera implementation of the sensor that would enable high-speed optical testing. OCIS codes: 010.7350, 220.4840, 120.4640.

Published
2007

47. Phase-aberration correction with dual liquid-crystal spatial light modulators

Author

Kelly, Thu-Lan and Munch, Jesper

Subjects
Aberration -- Analysis, Crystal optics -- Analysis, Liquid crystals -- Analysis, Spatial light modulators -- Analysis, Astronomy, Physics
Abstract

A phase-aberration-correction system that uses high-resolution, twisted nematic liquid-crystal spatial light modulators in a Mach-Zehnder interferometer is presented. A correction algorithm is described and experimentally verified by use initially of one liquid-crystal panel. Phase aberrations are successfully removed by a single liquid-crystal panel, but unacceptably high amplitude variation is introduced into the wave front because of the phase-amplitude coupling of the spatial light modulator. A second panel is used to remove the amplitude modulation. The modified optical system with a multiplicative architecture is described, and results are presented that show the correction of phase aberrations with an amplitude variation of less than 10%.

Published
1998

48. CRISTAL: protocol for a cluster randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study

Author

Sidhu, Verinder Singh, primary, Graves, Steven E, additional, Buchbinder, Rachelle, additional, Naylor, Justine Maree, additional, Pratt, Nicole L, additional, de Steiger, Richard S, additional, Chong, Beng H, additional, Ackerman, Ilana N, additional, Adie, Sam, additional, Harris, Anthony, additional, Hansen, Amber, additional, Cripps, Maggie, additional, Lorimer, Michelle, additional, Webb, Steve, additional, Clavisi, Ornella, additional, Griffith, Elizabeth C, additional, Anandan, Durga, additional, O'Donohue, Grace, additional, Kelly, Thu-Lan, additional, and Harris, Ian A, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results